

Zydus receives final approval for Pyridostigmine Bromide Tablets

Ahmedabad, 24 June 2015

Zydus Cadila has received the final approval from the USFDA to market Pyridostigmine Bromide Tablets USP, 60 mg.

The estimated sales in 2015 for Pyridostigmine Bromide Tablets USP which is used in the treatment of various neurological disorders is USD 27.9 million as per IMS.

The group now has 100 approvals and has so far filed over 260 ANDAs since the commencement of the filing process in FY 2003-04.
